Antibody therapy of lymphoma
Antibody therapy of lymphoma
The availability of rituximab and the possible imminent availability of two new radiolabelled monoclonal anti-CD20 antibodies (Yttrium-90 (90Y)-ibritumomab and Iodine-131(131I)-tositumomab) have captured much attention in the treatment of lymphoma. The chimeric monoclonal anti-CD20 antibody, rituximab has truly heralded a new era for the treatment of lymphoma and human malignancies. The full potential of antibody-based therapy to improve the outcome in patients with B-cell non-Hodgkin’s lymphoma has yet to be defined, but recent data suggests that the combination of chemotherapy plus rituximab may significantly improve outcome for patients with aggressive lymphoma over chemotherapy alone. Highly promising data are also emerging for the use of rituximab in combination with chemotherapy in other types of lymphoma. New advances in antibody therapy, driven by new technologies and defining novel antigen targets, offer the promise of more effective tumour specific therapies. Combinations of antibodies, either conjugated with radioisotopes or unlabelled, used with chemotherapy are likely to provide definitive advances in the treatment of lymphoma in the immediate future.
immunotherapy, monoclonal antibody, non-Hodgkin’s lymphoma, radioimmunotherapy, rituximab
953-961
Bayne, M.C.
aa59681b-c38c-4371-8f2e-32bba0467658
Illidge, T.M.
43b02dd8-7761-4781-b10b-877e26222508
2001
Bayne, M.C.
aa59681b-c38c-4371-8f2e-32bba0467658
Illidge, T.M.
43b02dd8-7761-4781-b10b-877e26222508
Bayne, M.C. and Illidge, T.M.
(2001)
Antibody therapy of lymphoma.
Expert Opinion on Pharmacotherapy, 2 (6), .
Abstract
The availability of rituximab and the possible imminent availability of two new radiolabelled monoclonal anti-CD20 antibodies (Yttrium-90 (90Y)-ibritumomab and Iodine-131(131I)-tositumomab) have captured much attention in the treatment of lymphoma. The chimeric monoclonal anti-CD20 antibody, rituximab has truly heralded a new era for the treatment of lymphoma and human malignancies. The full potential of antibody-based therapy to improve the outcome in patients with B-cell non-Hodgkin’s lymphoma has yet to be defined, but recent data suggests that the combination of chemotherapy plus rituximab may significantly improve outcome for patients with aggressive lymphoma over chemotherapy alone. Highly promising data are also emerging for the use of rituximab in combination with chemotherapy in other types of lymphoma. New advances in antibody therapy, driven by new technologies and defining novel antigen targets, offer the promise of more effective tumour specific therapies. Combinations of antibodies, either conjugated with radioisotopes or unlabelled, used with chemotherapy are likely to provide definitive advances in the treatment of lymphoma in the immediate future.
This record has no associated files available for download.
More information
Published date: 2001
Keywords:
immunotherapy, monoclonal antibody, non-Hodgkin’s lymphoma, radioimmunotherapy, rituximab
Identifiers
Local EPrints ID: 26392
URI: http://eprints.soton.ac.uk/id/eprint/26392
ISSN: 1465-6566
PURE UUID: aa17d98f-e7fe-42bd-8e53-3b263b617762
Catalogue record
Date deposited: 24 Apr 2006
Last modified: 22 Jul 2022 20:34
Export record
Contributors
Author:
M.C. Bayne
Author:
T.M. Illidge
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics